1Loftus IM,Naylor AR, Bell PR, et al. Matrix metalloproteinases and atherosclerotic plaque instability. Br J Surg,2002,89:680-694.
2Loftus IM, Naylor R, goodall S, et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke,2000,31:40-47.
3Chen XZ,Lu BX.Matrix metalloproteinases and cerebrovascular disease. Cerebrovascular Disease Foreign Medical Science,1999,7:197-200.陈兴洲,陆兵勋.基质金属蛋白酶与脑血管病.国外医学脑血管病分册,1999,7:197-200.
4Falke P, Elneihoum AM, Ohlsson K. Leukocyte activation: relation to cardiovascular mortality after cerebrovascular ischemia. Cerebrovasc Dis,2000,10:97-101.
5The diagnosis outlines of cerebrovascular diseases. The 4th chinese conference on cerebrovascular diseases. Chin J of Neurol, 1996,29:381. 各类脑血管病诊断要点. 全国第四届脑血管病学术会议. 中华神经科杂志,1996,29:381.
6Mach F, Schonbeck U, Fabunmi RP, et al. T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation. Am J Pathol,1999,154:229-238.
7Xie YQ, Yang QD. Research Developments of MMP-2、MMP-9 and cerebrovascular ischemia. Foreign Medical Sciences Section on Neurol and Neurosurg, 2000,27:172-174.谢逸群,杨期东.MMP-2、MMP-9与脑缺血损伤研究进展.国外医学神经病
8Newby AC, Libby P, van der Wal AC. Plaque instability--the real challenge for atherosclerosis research in the next decade? Cardiovasc Res, 1999,41:321-322.
9Altieri P, Brunelli C, Garibaldi S, et al. Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest,2003,33:648-656.
10Reynolds MA, Kirchick HJ, Dahlen JR, et al. Early biomarkers of stroke. Clin Chem,2003,49:1733-1739.
2Young RP, Hopkins R, Eaton EA, et al. Potential benefits of st-atins on morbidity mortality in chronic obstructive pulmon-ary disease : a re- view of the evidence[J]. Postgrad Med J, 2009, 85:414-421.
